Roivant Q4/FY2023: VTAMA net rev $13.7M, $28.0M FY; RVT-3101 UC data positive; cash $1.7B; FY loss $1.23B

Roivant Sciences Ltd.

VTAMA net product revenue $13.7M in Q4, $28.0M FY; 170k prescriptions since launch; 76% US commercial lives covered.
RVT-3101 improved efficacy from week 14 to week 56 in Phase 2b UC study; Phase 2 Crohn's initiated, data expected Q4 2024.
VTAMA met primary and all secondary endpoints in Phase 3 ADORING 1/2 for atopic dermatitis in 813 patients including children aged 2+.
Cash and equivalents $1.7B at March 31, 2023; cash runway into H2 2025. GAAP loss from continuing ops $175M Q4 ($0.20/share).
FY2023 GAAP loss from continuing ops $1.23B ($1.58/share); net loss attributable to Roivant $1.01B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for the fourth quarter and fiscal year ended March 31, 2023.

Period: the fourth quarter and fiscal year ended March 31, 2023
Result: reported results

Exact text from the filing

On June 28, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended March 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-031794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.